.) developed rescued spottinglethal rats that carry a naturally occurring deletion of the endothelin (ET) type B receptor gene resulting in a lack of functional renal ETB receptor expression. It has been shown that rats homozygous (sl/sl) for the deletion have elevated plasma ET-1 levels; thus, the purpose of this study was to determine whether this deletion would result in a downregulation of ETA receptors in renal tissue. ET-1 and ET-3 binding experiments were performed with cortex, outer medullary, and inner medullary membranes of heterozygous (sl/ϩ) and sl/sl ETB receptor-deficient rats.
affinity to each of the ET isopeptides, location, and their biological function (18) . Endothelin A (ET A ) receptors bind ET-1 with higher affinity than ET-2 or ET-3, are localized to vascular smooth muscle cells, and cause vasoconstriction. Endothelin B (ET B ) receptors are found on endothelial cells and have been shown to produce vasodilation and bind all three ET isopeptides with equal affinity. Additionally, there is evidence that ET B receptors in pulmonary endothelial cells "clear" ET-1 from the circulation (7) . However, this classification of ET receptors may be oversimplified, with increasing evidence suggesting additional receptor subtypes. It is now known that there exist two pharmacologically distinct subtypes of the ET B receptor, ET B1 and ET B2 , whose biological activity is a function of their localization. ET B1 are located on the vascular endothelium and produce vasodilation upon agonist binding, whereas ET B2 are found on vascular smooth muscle cells and mediate non-ET A vasoconstriction.
Within the kidney, both ET receptor subtypes have been identified in various regions differing both in number and function. In both cortex and medulla, ET B receptors are more abundant than ET A receptors (24) . The ET B receptor has been localized to renal arterioles, glomeruli, proximal convoluted tubule, medullary thick ascending loop, and collecting duct (29) . ET B receptors in the renal vasculature couple to nitric oxide and prostaglandin synthesis, leading to vasorelaxation (6) , whereas ET B receptors on renal tubular cells promote natriuresis and diuresis (8, 20) . ET A receptors localized in arterioles and proximal tubules mediate vasoconstrictor (5, 20) and antinatriuretic effects (18, 26) .
Elevated plasma levels of ET-1 have been implicated in the pathogenesis of many disease models, including pulmonary hypertension (2) and DOCA salt hypertension (27) . Although plasma ET-1 levels are high in these disease models, there is still conflicting evidence as to the regulation of ET receptors. Studies by Bauer et al. (2) have shown increased mRNA transcripts encoding the ET B receptor with no difference in ET A mRNA levels in pulmonary arterial tissue taken from patients with pulmonary hypertension. However, in endothelium-denuded saphenous veins from AfricanAmerican patients with essential hypertension, elevated plasma ET-1 levels may be responsible for a decrease in ET A mRNA expression together with increased ET B mRNA levels (13) . In DOCA-salt hypertensive rats, Pollock et al. (27) observed increased ET B receptor number with an apparent decrease in ET A receptor number in the renal medulla. Conversely, a transient elevation of plasma ET-1 levels induced by adenovirus gene transfer led to systemic hypertension but no change in renal ET receptor number (28) .
The spotting-lethal rat carries a natural 301-bp deletion in the ET B receptor that abrogates expression of functional ET B receptors. Rats that are homozygous (sl/sl) for this mutation exhibit a lethal phenotype of congenital intestinal agangliosis and are commonly used as a model for Hirschsprung's disease (9) . In 1998, Gariepy et al. (11) used a dopamine-␤-hydroxylase promoter to direct transgenic ET B receptor expression in adrenergic tissue that "rescued" the rats from the intestinal defect. The sl/sl animals have elevated plasma ET-1 levels. Therefore, the purpose of this study was to determine whether ET B receptor deficiency and elevated plasma ET-1 levels are associated with changes in ET receptor density in the kidney.
METHODS
Membrane preparations. All of the procedures carried out on the rats were approved by the Medical College of Georgia Animal Care and Use Committee and followed the guidelines of the American Physiological Society. Rats (300-350 g) heterozygous and homozygous for the ET B receptor deficiency from our local breeding colony and male Sprague-Dawley (Harlan) rats (300-350 g) were anesthetized, and kidneys were excised and separated with a razor blade on ice into cortex, outer medulla, and inner medulla and frozen at Ϫ80°C. Tissue was weighed, pulverized, and then homogenized in buffer containing 250 mM sucrose, 50 mM Tris⅐HCl, 5 mM EDTA, and 15 M phenylmethylsulfonyl fluoride (PMSF), pH 7.4, as described (27) . Briefly, homogenized samples were then centrifuged at 1,000 g at 4°C for 30 min. The supernatant was further centrifuged at 30,000 g at 4°C for 45 min, and the resulting pellet was resuspended in one-half of the starting volume of homogenization buffer and frozen at Ϫ80°C. The protein concentration of the membrane preparations was determined by the Bradford method (Bio-Rad, Hercules, CA).
Saturation binding curves. Receptor binding curves were performed to quantify the amount of ET receptors in the cortex, outer medulla, and inner medulla of sl/ϩ or sl/sl rats for the ET B receptor deficiency. Sprague-Dawley rat renal tissue was also used in preliminary experiments to serve as a comparison to both previously published data and the transgenic animals. Membrane preparations from each of the three renal tissue sections were bound to wheat germ agglutinin scintillation proximity beads as previously described (27) . Briefly, membrane preparations of sl/ϩ or sl/sl ET B receptor-deficient rats from renal cortex (20 g), outer medulla (20 g), or inner medulla (5 g) were added to each well of a 96-well microtiter plate (Optiplate; Packard Instruments, Meridian, CT). Wheat germ agglutinin polyvinyltoluene beads (scintillation proximity beads; Amersham Life Science, Arlington Heights, IL) were suspended in binding buffer (40 mg/ml), with 1 mg added to each well. Binding buffer consisted of 20 mM Tris⅐HCl, 100 mM NaCl, 10 mM MgCl 2, and 3 mM EDTA, pH 7.4, with additional 0.1 mM PMSF, 5 g/ml pepstatin A, 0.025% bacitracin, and 0.2% BSA. The plate was covered and shaken for 3 h at room temperature to allow for coupling of the protein to the beads. After this precoupling, 25 l of binding buffer were added to wells for total binding determination, whereas 2 M ET-1 or ET-3 was added to determine nonspecific binding. [ The plate was sealed and shaken for 18 h at room temperature. The plate was then centrifuged for 5 min at 1,000 g before being counted on a Packard TopCount microplate scintillation counter. Our laboratory had previously determined optimum incubation times and procedures (27) . All measurements were performed in duplicate, and all dilutions of radioactive and nonradioactive peptides were made in siliconized tubes.
Additional experiments were performed using whole kidney homogenate or separated renal inner medulla from sl/ϩ and sl/sl animals that were homogenized as described above. Protein from whole kidney homogenate (90 g) or inner medulla (5 g) was added to wells followed by precoupling to scintillation proximity beads. Unlabeled ET-1 (2 M) was added to wells to determine nonspecific binding, whereas the total binding wells received buffer. Radiolabeled ET-1 (1 nM) was added to all wells, and the plate was covered, shaken for 18 h at room temperature, and then counted on the microplate scintillation counter.
Competition binding curves. Competition binding curves were performed using selective ET A and ETB receptor antagonists. Preliminary experiments were performed using inner medullary tissue preparations from Sprague-Dawley animals. Membrane preparations from the inner medulla (5 g) of sl/ϩ or sl/sl animals were precoupled to scintillation proximity beads similar to the same receptor binding protocol described above. For generation of competition binding curves, either the ETA receptor antagonist A-127722 (0.01 pM-0.5 mM), the ETB receptor antagonist A-192621 (100 pM-10 mM), or unlabeled ET-1 (10 pM-1 M) was added to separate wells followed by the addition of Data and statistical analysis. Receptor binding data were analyzed by nonlinear regression using the one-site model of the binding isotherm except for the Scatchard analysis of [ 125 I]ET-1 binding in inner medulla of sl/sl animals in which a two-site model was utilized (Prism; GraphPad Software, San Diego, CA). Statistical differences in the mean values for all binding data were determined by ANOVA, and Fisher's protected least-significant difference test was used to determine differences between individual means (StatView, Abacus Concepts, Berkley, CA). Values are reported as means Ϯ SE, with P Ͻ 0.05 and P Ͻ 0.001 considered significant. (Fig. 1A) and renal outer medulla (Fig. 1B) of sl/ϩ ET B receptor-deficient rats. Additionally, ET-1 binding in cortex and outer medullary preparations from sl/sl rats was less than one-half that observed in sl/ϩ rats. Specific binding of ET-1 in the inner medulla was eightfold higher in both sl/sl and sl/ϩ rats compared with the cortex and outer medulla. Figure 4 represents B max values from renal cortical (Fig. 4A) , outer medullary (Fig. 4B) , and inner medullary (Fig. 4C) 125 I]ET-1 to either 5 g inner medullary membrane preparations (n ϭ 3 animals/group) or 90 g whole kidney membrane preparations (n ϭ 3 animals/group) from sl/ϩ and sl/sl ETB-deficient rats. Values are means of nonspecific binding subtracted from total binding Ϯ SE. Statistical analysis was performed using Student's t-tests with ** P Ͻ 0.001. A-127722, the ET A receptor antagonist, had the lowest affinity (IC 50 7.3 Ϯ 0.11 M; Table 2 ). However, competition binding curves performed on inner medullary membrane preparations from sl/sl rats were quite different (Fig. 6B) (Table 2) , similar to that of the sl/ϩ rat. The ET B receptor antagonist was next highest in affinity for the receptor (IC 50 0.10 Ϯ 0.04 M; Table 2 ), again similar to results from the sl/ϩ rat, whereas the ET A receptor antagonist had the least affinity of the three ligands, with an IC 50 value of 20.7 Ϯ 0.69 M ( Table 2) . Taken together, results from the saturation binding curves suggest that there is an ET-3 binding site in the inner medulla of sl/sl rats and that competition binding curves suggest that this site binds the ET A receptor antagonist with very high affinity.
RESULTS
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The present study was conducted to determine if any changes in ET A receptor binding in the kidney would occur under conditions of ET B receptor deficiency that is associated with chronic elevations in circulating ET-1 levels. We hypothesized that long-term exposure to ET-1 would cause a downregulation of ET A receptor expression. Indeed, results showed that ET A receptor binding was reduced significantly in renal tissue of sl/sl compared with sl/ϩ rats. These observations are consistent with a compensatory change in ET A receptor expression when ET B receptor function is lost and plasma levels of ET-1 are increased. An unexpected observation was evidence for a novel ET-3 binding site in the renal inner medulla of ET B receptor-deficient animals.
Saturation binding curves using radiolabeled ET-1 reveal an expected decrease in overall ligand-receptor binding interactions in all three regions of kidneys from sl/sl compared with sl/ϩ rats. Consistent with previous studies, B max values determined from ET-1 binding were ϳ10-fold greater in the inner medulla compared with the cortex and outer medulla of both sl/ϩ and sl/sl rats, highlighting the abundance of ET receptors in this region (16) . However, when ET-1 saturation binding results were plotted using Scatchard analysis, the inner medulla from sl/sl rats revealed a surprising two-site model, whereas a linear one-site model was detected in the sl/ϩ inner medulla. This two-site model found in the sl/sl rat indicated that there was another ET binding site that was different from both ET A and ET B receptors. When the results from both the ET-1 and ET-3 saturation curves were plotted as a function of receptor number, the total amount of ET receptors was significantly greater in the inner medulla of both sl/ϩ and sl/sl animals compared with their respective cortex and outer medulla, with the majority of receptors representing the ET B subtype. However, B max values were substantially lower in both sl/ϩ and sl/sl rats compared with published values from Sprague-Dawley rats (24) . The reason for this difference may be related to methodology but could be because of differences in rat strain that have yet to be discerned.
We performed additional experiments to compare previously published ET-1 binding data using whole kidney homogenates with similar whole kidney preparations from sl/ϩ and sl/sl rats (11) . When sl/ϩ whole kidney or inner medulla membranes were used, ligand-receptor binding was similar between the two preparations. However, the same experiment performed on sl/sl preparations indicates that significant ET-1 binding occurs only when the inner medulla was separated from the cortex and outer medulla, and this binding is "diluted out" when included in a whole kidney preparation. This led us to examine the nature of this binding site through competition binding curves using specific ET A and ET B receptor antagonists. Findings from competition binding curves using radiolabeled ET-1 in sl/ϩ inner medullary preparations indicated that the ET B receptor antagonist had less affinity compared with the natural ligand, ET-1 but more affinity for the receptor than the ET A receptor antagonist. However, within the sl/sl inner medulla, the ET A receptor antagonist had very high affinity, greater than either ET-1 or the ET B antagonist.
The sl/sl animal is devoid of ET B receptor apart from adrenergic tissue where its expression in these regions is essential for survival (9) . Because plasma ET-1 levels are elevated, these animals have had to adapt to the loss of renal ET B receptor function in the face of high circulating ET-1. Plasma ET-1 levels in sl/sl rats are significantly elevated compared with sl/ϩ rats, and results from this colony of rats have been published previously (25) . Consistent with our original hypothesis, the sl/sl rat appears to downregulate ET A receptors in renal cortical and outer medullary tissue. However, the situation in the renal inner medulla appears more complex. Within the inner medulla, there is not a downregulation of ET A receptors. In fact, ET A receptor number is similar to those found in the sl/ϩ inner medulla. Additionally, our studies provide evidence for the existence of a unique binding site that has the novel characteristics of having a high affinity for ET-3 that competes with an ET A receptor antagonist. We can only speculate, at this point, that this novel binding site represents some form of compensation for the lack of functional ET B receptors in this region of the kidney. More exhaustive biochemical studies will be needed to determine why this novel binding site has a different binding profile from the traditional ET A or ET B receptor. Further studies exploring the possibility that this novel binding site is actually a putative ET receptor along with its estimated size, biochemical behavior, and its pharmacological profile against multiple ET-related ligands are clearly warranted. In addition, to determine whether this binding site is unique to the renal inner medulla, receptor binding experiments will need to be performed using tissue from the sl/sl animals that normally are enriched with ET B receptors, such as the lungs and the cerebellum.
The physiological significance of this novel ET binding site has yet to be determined, but we can speculate that it could be of importance in models of hypertension that have elevated circulating ET levels. In the DOCA-salt rat model of hypertension, it has been shown that plasma ET-1 levels are elevated compared with placebo-treated controls (1). Additionally, it has been shown that there is an upregulation of ET B receptors in the renal medulla from DOCA-salt rats whose function is thought to promote sodium and water excretion (27) . Thus the DOCAsalt model of hypertension is associated with elevated ET-1 levels, and the kidney responds by upregulating renal medullary ET B receptors. In rats that lack functional ET B receptors, there are also elevated plasma ET-1 levels, and these animals have elevated blood pressures (10); we would expect the kidney to respond by upregulating medullary ET B receptors. However, because there is a mutation in the ET B receptor gene, we speculate that the sl/sl animal tries to compensate by expressing a renal inner medullary ET binding site that has a unique binding profile different from that of the ET A and ET B receptors. We can speculate further that it may influence blood pressure because of its ET A receptor-like sensitivity to the ET A antagonist but might also function to promote natriuresis because of its ET B receptor-like binding of ET-3. Future studies are required to determine if this renal inner medullary binding site has functional significance under normal physiological conditions.
There is anecdotal evidence for the existence of a third class of ET receptors, named ET C . By definition, the ET C receptor has a rank order of affinity of ET-3 Ͼ ET-1 in radioligand binding and functional studies. In 1993, Karne et al. (17) cloned an ET C -like receptor that has high affinity for ET-3 from Xenopus dermal melanophores. However, no ET C receptor has yet been cloned from mammalian sources (17) . The possibility arises that the ET-3 binding site is unmasked in the renal inner medulla of the sl/sl ET B -deficient animal and could be the mammalian counterpart to the ET C receptor found in Xenopus melanophores. In addition, Zeng and colleagues (34) (24) demonstrated the existence of a splice variant of the ET B receptor in porcine cerebellum that differs in the last 32 amino acids of the COOH-terminal tail from that of the wild-type receptor but that binding and stimulation of inositol phosphate production are identical to that found in the wild type. Radioligand binding data also indicated that the splice variant and the wild-type ET B receptor are expressed at the same level in the porcine brain. Additionally, Tsutsumi et al. (30) provide evidence of a novel ET B receptor transcript that could potentially generate a new receptor. It should be noted that the dopamine-␤-hydroxylase ET B receptor transgene was constructed using the ET B cDNA, that is, it does not contain ET B gene introns, making splice variants from the transgene unlikely.
The sl/sl ET B -deficient animal has a 301-bp deletion in the gene encoding for the first two membrane-spanning regions of the receptor, and this shortened transcript does not encode functional ET B receptors (11) , normally, the part of the NH 2 -terminal domain that is in close proximity to the first transmembrane region required for ligand binding. Through proteolytic truncation experiments, it has been shown that ET-1 binds to a 29-amino-acid sequence in the NH 2 -terminal region of the ET B receptor near the first transmembranespanning domain (18, 31) . Thus we can speculate that ET-3 binding in the sl/sl inner medulla must be to an ET-like receptor that contains an NH 2 -terminal region of 29 amino acids near the first transmembrane segment. Future studies will need to be completed to address whether this binding site has an alteration at the COOH-terminal region of the receptor.
In summary, our data suggest that there is a reduction in ET A receptor number in the cortex and outer medulla of rats deficient of functional ET B receptor consistent with a downregulation related to elevated circulating ET-1 levels. Furthermore, we provide evidence for an ET-3 binding site within the inner medulla of ET B receptor-deficient rats that binds the ET A antagonist, A-127722, with very high affinity. We speculate that this binding site is a novel ET receptor that is unmasked during ET B receptor deficiency.
